The firm told investors it’s given up on the troubled drug maker, which has badly hurt its funds in 2016, and has embarked on a “period of introspection” over its performance.
Jonathan Auerbach’s Tiger Seed absorbs twin blows: the rise and fall of Valeant and Altice. The firm is hanging on, however, and waiting for the rebound.
